Clinical Trial

SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer

Chetan Pujara, Ph.D Chief Research & Development Officer, SpyGlass Pharma Dr. Pujara brings extensive industry experience to guide late-stage development…

9 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…

9 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

BOULDER, Colo., March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced…

9 months ago

Medrio Enhances RTSM For Faster Clinical Trial Starts and Greater Flexibility

SAN FRANCISCO, March 26, 2025 /PRNewswire/ -- Medrio, a global leader in clinical trial technology, today announced enhancements to its randomization…

9 months ago

Rarecells Inc. Appoints Dr. Neil Kurtz to Board of Directors

NEW YORK and PARIS, March 26, 2025 /PRNewswire/ -- Rarecells Inc., a pioneering company in liquid biopsy technology, is pleased…

9 months ago

DATAcc by DiMe Releases Resources to Build the Business Case for Digital Endpoints

New tools will calculate the ROI of using digital endpoints in clinical trials, empowering greater innovation in research BOSTON, March…

9 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.…

9 months ago

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D

AZURE-1 will evaluate the efficacy and safety of brelovitug compared to delayed treatmentREDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE)…

9 months ago

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”…

9 months ago

Aligos Therapeutics Presents Positive Data at APASL 2025

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…

9 months ago